Curated News
By: NewsRamp Editorial Staff
January 09, 2026
Soligenix Hits CTCL Trial Milestone, Zacks Maintains $25 Valuation
TLDR
- Soligenix's Phase 3 FLASH2 trial shows a 48% blinded response rate, offering investors a potential advantage with Zacks' $25 per share valuation and an attractive risk-reward profile.
- Soligenix reached milestone enrollment in its Phase 3 FLASH2 trial for HyBryte, with a 48% blinded response rate in CTCL patients, leading to a $25 per share valuation based on probability-adjusted discounted cash flow.
- Soligenix's HyBryte therapy for cutaneous T-cell lymphoma addresses an unmet medical need, potentially improving treatment for rare diseases and enhancing patient quality of life worldwide.
- Soligenix's novel photodynamic therapy uses safe visible light to treat CTCL, with a 48% response rate and a $25 per share valuation from Zacks Research.
Impact - Why it Matters
This news matters because it highlights a significant advancement in treating cutaneous T-cell lymphoma, a rare and often debilitating cancer with limited therapeutic options. HyBryte's promising 48% response rate in Phase 3 trials could offer a safer, visible-light-based alternative to existing treatments, potentially improving patient outcomes and quality of life. For investors, the maintained $25 per share valuation by Zacks suggests confidence in Soligenix's pipeline, including not only HyBryte but also other rare disease therapies and public health vaccines, positioning the company as a key player in addressing unmet medical needs. The progress underscores the broader importance of biopharmaceutical innovation in tackling rare diseases and global health threats, with implications for healthcare costs and patient access to novel therapies.
Summary
Soligenix (NASDAQ: SNGX), a New Jersey-based biopharmaceutical company focused on rare diseases, has reached a critical milestone in its confirmatory Phase 3 FLASH2 trial for HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). The trial achieved its 50-patient enrollment target, with a blinded response rate of 48% among completed patients, signaling strong clinical progress. Zacks Small-Cap Research's updated analysis, highlighted in an article discussing the company, maintains a $25 per share valuation based on probability-adjusted discounted cash flow models, expressing confidence in the trial's direction while noting market puzzlement at the subdued response. The next major catalyst is the second quarter 2026 interim analysis, which could further validate HyBryte's potential.
Beyond HyBryte, Soligenix's Specialized BioTherapeutics segment includes expansion into psoriasis with SGX302 and development of innate defense regulator technology like SGX942 for oral mucositis and SGX945 for Behçet's disease. The company's Public Health Solutions segment, supported by government grants, focuses on vaccine candidates such as RiVax® for ricin toxin, filovirus vaccines, and CiVax™ for COVID-19, utilizing its proprietary ThermoVax® heat stabilization platform. For further details, visit the company's website at www.Soligenix.com, and to view the full article, visit https://ibn.fm/e9XQ5. Additional updates are available in the company's newsroom at https://ibn.fm/SNGX, part of the Dynamic Brand Portfolio managed by MissionIR, a communications platform within the InvestorBrandNetwork that enhances corporate visibility through syndicated content and press distribution.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Hits CTCL Trial Milestone, Zacks Maintains $25 Valuation
